EP
INO icon

Eversept Partners’s Inovio Pharmaceuticals INO Stock Holding History

Eversept Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.14M Hold
1,035,360
– – 0.06% 104
2026
Q1 		$1.8M Buy
+1,035,360
New +$1.7M 0.1% 92

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners's INO Position: Q2 2026 in Review

Eversept Partners held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 1,035,360 shares worth $1.14M. The position accounts for 0.06% of the portfolio, ranked #104.

Eversept Partners first reported a position in INO in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.8M in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Eversept Partners held 1,035,360 shares of Inovio Pharmaceuticals worth $1.14M as of Q2 2026.
  • Eversept Partners left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up 0.06% of Eversept Partners's portfolio in Q2 2026, its #104 holding.
  • Eversept Partners first reported a position in Inovio Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Eversept Partners's Inovio Pharmaceuticals position peaked at $1.8M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.